Endologix to Present in Two Upcoming Healthcare Conferences

IRVINE, Calif.--(BUSINESS WIRE)-- Endologix Inc. a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the company will be presenting in two upcoming healthcare conferences:

• The 2023 Stifel Healthcare Conference
  Wednesday, November 15, 2023, at 10:55 AM Eastern Time.
  
• Canaccord Genuity Medical Technology and Diagnostics Forum
  Thursday, November 16, 2023, at 9:30 AM Eastern Time.

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231109601690/en/